NKTR — NEKTAR THERAPEUTICS

Nasdaq · Health Care · Pharmaceuticals · CIK 906709 ·
Last close
$70.67
Market Cap
$2.39B
52W High
$88.10
52W Low
$54.13
ADV30
1,102,183
Next earnings
2026-08-13

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 10,861,000 -38,258,000 -44,904,000 763,271,000 149,578,000 187,055,000
Dec 2025 21,807,000 21,807,000 -19,090,000 -36,079,000 280,406,000 15,116,000 190,574,000
Sep 2025 11,790,000 11,790,000 -31,532,000 -35,522,000 301,347,000 41,032,000 216,261,000
Jun 2025 11,175,000 11,175,000 -35,783,000 -41,593,000 207,534,000 42,988,000 231,745,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-208,511,000
Investing CF
$-1,197,000
Financing CF
$180,566,000
CapEx
$-171,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-10.20
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-3,760,286,000
Inventory
Receivables
$1,779,000
ST Investments
$230,636,000
EBIT TTM
$-129,303,000
Pretax Income TTM
$-155,487,000
Interest Exp TTM
$26,184,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$55,633,000
EBITDA
$-123,912,000
Free Cash Flow
$-107,228,376
Enterprise Value
$1,962,486,912
Total Cash
$568,604,032
Total Debt
$143,432,000
Shares Out
33,786,032
Trailing EPS
$-7.93
Book Value
$19.55
ROE
-53.6%
ROA
-15.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 55,232,000 -130,771,000 -164,076,000 280,406,000 190,574,000 -208,511,000
Dec 2024 98,427,000 -129,918,000 -118,961,000 303,850,000 243,113,000 -175,709,000
Dec 2023 90,122,000 -135,225,000 -276,056,000 398,033,000 267,046,000 -192,606,000
Dec 2022 92,055,000 -240,236,000 -368,198,000 710,600,000 343,962,000 -304,007,000

TTM Snapshot

Revenues TTM
$105,757,000
NetIncome TTM
$-495,945,000
OpCashFlow TTM
$0
Assets (Latest)
$710,600,000
Forward EPS
$-11.87

Max Pain — expiry 2026-08-21

max pain strike: $65.00 · spot: $70.67 · call oi: 9,069 · put oi: 5,329
Expected Move to 2026-08-21: ±$8.70 (12.31%) — implied range $61.97$79.37 · ATM straddle on $70.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PBH Prestige Consumer Healthcare Inc. $2.38B $50.22
NRIX Nurix Therapeutics, Inc. $2.41B $23.21
RARE Ultragenyx Pharmaceutical Inc. $2.45B $24.91
VERA Vera Therapeutics, Inc. $2.30B $32.10
GIFOF Grifols SA $2.29B $8.85

News headlines (Yahoo Finance, 1h cache)

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
2026-07-28 22:00 · Yahoo
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
2026-07-28 13:55 · Yahoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-24 20:15 · Yahoo
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2026-07-21 11:00 · Yahoo
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
2026-07-03 00:41 · Yahoo
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
2026-06-24 19:59 · Yahoo
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
2026-06-23 11:55 · Yahoo
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility
2026-06-07 03:10 · Yahoo
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
2026-06-05 15:55 · Yahoo
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
2026-05-27 22:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.